Schering Corporation

Merck Sharp + Dohme Corp.

Other

Chaoyang Dai

M Arshad Siddiqui

Joseph A Kozlowski

Wensheng Yu

Janeta Popovici-Muller

Dansu Li

Brian J Lavey

Vinay M Girijavallabhan

Guowei Zhou

Kristin E Rosner

Ling Tong

Michael K C Wong

De-Yi Yang

Neng-Yang Shih

Bandarpalle B Shankar

Seong Heon Kim

Razia Rizvi

Lei Chen

Robert Feltz

Zhuyan Guo

Peter Orth

Vincent Stewart Madison

Umar Faruk Mansoor

Liping Yang

Aneta Maria Kosinski

Aneta M Micula

Lianyun Zhao

David Benjamin Belanger

Judson E Richard

Luke Fire

Angie R Angeles

Seong-Heon Kim

Zhaoning Zhu

Brian Alexander McKittrick

Gerald Wayne Shipps, Jr

Pauline C Ting

Sunil Paliwal

Robert D Mazzola, Jr

Tin-Yau Chan

Matthew H Daniels

Andrew J McRiner

Zhaoyang Meng

Panduranga Adulla P Reddy

Henry A Vaccaro

Mehul F Patel

Patrick J Curran

Shuyi Tang

Duan Liu

Yang Nan

Shing-Chun C Wong

Amit K Mandal

Lalanthi Dilrukshi Vitharana

Lalalnthi Dilrukshi Vitharana

Shankar B Bandarpalle

Andrew Mcriner

Matthew Hersh Daniels

Michael KC Wong

Aneta S Micula

Robert Schering-Plough Corporation Feltz

The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R, R, R, R, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors

The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. Formula I 

Compounds for inhibiting KSP kinesin activity

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

Compounds for the treatment of inflammatory disorders

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF&#x2014;or combinations thereof. 

This invention relates to compounds of the Formula (I): 

This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-&#x3b1; or combinations thereof.

Growing community of inventors

Acton, MA, United States of America

Chaoyang Dai